Haisco Pharmaceutical Group Co., Ltd.

002653

CNE100001BC7

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-05-28 EDT			5-day change	1st Jan Change
31.35 ^CNY	+4.12%		+2.38%	+35.42%

05-16	Chinese Drug Regulator Accepts Haisco Pharma's Application for Pulmonary Disease Drug	MT
04-19	Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Xizang Haisco Pharmaceutical Group Co., Ltd. Approves the Election of Chen Long as Independent Director

June 24, 2013

Xizang Haisco Pharmaceutical Group Co., Ltd. announced at its EGM held on June 24, 2013, shareholders approved the election of Chen Long as independent director.

Latest news about Haisco Pharmaceutical Group Co., Ltd.

Chinese Drug Regulator Accepts Haisco Pharma's Application for Pulmonary Disease Drug	05-16	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-19	CI
Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules	04-18	MT
Haisco Pharma Gets Nod to Trial Asthma Drug	04-10	MT
Haisco Pharma Gets Nod to Trial HSK16149 Capsule as Central Neuropathic Pain Drug	04-01	MT
Haisco Pharma's Unit Gets Nod to Trial Drug for Hemolytic Diseases	03-25	MT
Haisco Pharma's Unit Gets Nod to Trial Tumor Drug Candidate	02-28	MT
Haisco Pharma to Set Up New Subsidiary in China’s Tibet Region	01-18	MT
Haisco Pharmaceutical Signs $462 Million Deal with Italy’s Chiesi Farmaceutici	11-21	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Haisco Pharmaceutical Group Co., Ltd. Announces Management Changes	23-08-27	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Haisco Pharmaceutical's Unit Gets Greenlight to Trial Diabetes Drug	23-08-14	MT
Haisco Pharma's Rupatadine Fumarate Tablets Passes Regulator's Evaluation	23-08-02	MT
Haisco Pharma’s Blood Clot Drug Passes Generic Consistency Evaluation in China	23-07-24	MT
Haisco Pharma Unit Gets Certification for Formula Food	23-06-27	MT
Haisco Pharma Gets Nod for HSK31679 Tablet Trial	23-06-26	MT
Haisco Pharma Unit Registers Nutritional Formula Food	23-05-17	MT
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Haisco Pharma Unit Gets Certificate for Two Food Supplements	23-04-17	MT
Haisco Pharmaceutical Wins Regulatory Nod to Trial Prostate Cancer Drug	23-04-06	MT
Haisco Pharmaceutical Gets Nod for China Clinical Trial of Lung Cancer Drug; Shares Jump 3%	23-03-16	MT
Haisco Pharmaceutical Wins Nod to Start Phase II Clinical Trial of Liver Disease Drug	23-03-15	MT
Haisco Pharmaceutical Unit's Compound Amino Acid Injection Passes Regulator's Consistency Evaluation; Shares Jump 4%	23-02-08	MT

Chart Haisco Pharmaceutical Group Co., Ltd.

Duration

Period

Chart Haisco Pharmaceutical Group Co., Ltd.

More charts

Haisco Pharmaceutical Group Co.,Ltd., formerly Xizang Haisco Pharmaceutical Group Co., Ltd., is a China-based company principally engaged in the research, development, manufacture and sale of new drugs and high-end medical instrument. The Companyâs main products are categorized into small volume injections, big volume injections, freeze-dried powder injections and others, which include polyene phosphatidylcholine injections, lipid solubility vitamins injection series, doradiazine methanesulfonate injections, nalmefene hydrochloride injections, fluprofen tromethamine tablets and cefoperazone sodium tazobactam sodium for injections, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Haisco Pharmaceutical Group Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.35 CNY

Average target price

36.19 CNY

Spread / Average Target

+15.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HAISCO PHARMACEUTICAL GROUP CO., LTD.	+35.42%	4.77B
ELI LILLY AND COMPANY	+39.22%	731B
NOVO NORDISK A/S	+32.62%	586B
JOHNSON & JOHNSON	-7.85%	348B
MERCK & CO., INC.	+15.48%	319B
ABBVIE INC.	-0.12%	273B
ASTRAZENECA PLC	+13.81%	235B
NOVARTIS AG	+7.67%	202B
ROCHE HOLDING AG	-6.87%	203B
PFIZER, INC.	-3.37%	158B

Other Pharmaceuticals

Haisco Pharmaceutical Group Co., Ltd.

Equities

002653

CNE100001BC7

Pharmaceuticals

Xizang Haisco Pharmaceutical Group Co., Ltd. Approves the Election of Chen Long as Independent Director

Latest news about Haisco Pharmaceutical Group Co., Ltd.

Chart Haisco Pharmaceutical Group Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Haisco Pharmaceutical Group Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals